View in EDS

A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.

Saved in:
Bibliographic Details
Title: A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Authors: Horn IP; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Marks DL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Koenig AN; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Hogenson TL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Almada LL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Goldstein LE; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Romecin Duran PA; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Vera R; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Vrabel AM; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Cui G; Division of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA., Rabe KG; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Bamlet WR; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Mer G; Division of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA., Sicotte H; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Zhang C; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Li H; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Petersen GM; Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA., Fernandez-Zapico ME; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: fernandezzapico.martin@mayo.edu.
Source: The Journal of biological chemistry [J Biol Chem] 2021 Jan-Jun; Vol. 296, pp. 100634. Date of Electronic Publication: 2021 Apr 03.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1083-351X (Electronic) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33823155
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Horn+IP%22">Horn IP</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Marks+DL%22">Marks DL</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Koenig+AN%22">Koenig AN</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Hogenson+TL%22">Hogenson TL</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Almada+LL%22">Almada LL</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Goldstein+LE%22">Goldstein LE</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Romecin+Duran+PA%22">Romecin Duran PA</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Vera+R%22">Vera R</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Vrabel+AM%22">Vrabel AM</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Cui+G%22">Cui G</searchLink>; Division of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Rabe+KG%22">Rabe KG</searchLink>; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Bamlet+WR%22">Bamlet WR</searchLink>; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Mer+G%22">Mer G</searchLink>; Division of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Sicotte+H%22">Sicotte H</searchLink>; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+C%22">Zhang C</searchLink>; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Li+H%22">Li H</searchLink>; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Petersen+GM%22">Petersen GM</searchLink>; Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Fernandez-Zapico+ME%22">Fernandez-Zapico ME</searchLink>; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: fernandezzapico.martin@mayo.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985121R%22">The Journal of biological chemistry</searchLink> [J Biol Chem] 2021 Jan-Jun; Vol. 296, pp. 100634. <i>Date of Electronic Publication: </i>2021 Apr 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%2E+on+behalf+of+American+Society+for+Biochemistry+and+Molecular+Biology%22">Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>2985121R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1083-351X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200219258%22">00219258 </searchLink><i>NLM ISO Abbreviation: </i>J Biol Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33823155
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jbc.2021.100634
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100634
    Titles:
      – TitleFull: A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Horn IP
      – PersonEntity:
          Name:
            NameFull: Marks DL
      – PersonEntity:
          Name:
            NameFull: Koenig AN
      – PersonEntity:
          Name:
            NameFull: Hogenson TL
      – PersonEntity:
          Name:
            NameFull: Almada LL
      – PersonEntity:
          Name:
            NameFull: Goldstein LE
      – PersonEntity:
          Name:
            NameFull: Romecin Duran PA
      – PersonEntity:
          Name:
            NameFull: Vera R
      – PersonEntity:
          Name:
            NameFull: Vrabel AM
      – PersonEntity:
          Name:
            NameFull: Cui G
      – PersonEntity:
          Name:
            NameFull: Rabe KG
      – PersonEntity:
          Name:
            NameFull: Bamlet WR
      – PersonEntity:
          Name:
            NameFull: Mer G
      – PersonEntity:
          Name:
            NameFull: Sicotte H
      – PersonEntity:
          Name:
            NameFull: Zhang C
      – PersonEntity:
          Name:
            NameFull: Li H
      – PersonEntity:
          Name:
            NameFull: Petersen GM
      – PersonEntity:
          Name:
            NameFull: Fernandez-Zapico ME
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2021 Jan-Jun
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1083-351X
          Numbering:
            – Type: volume
              Value: 296
          Titles:
            – TitleFull: The Journal of biological chemistry
              Type: main
ResultId 1